 
 
 
 
 
 
 
 
 
 
Δ
INTRODUCTION
Age is the major risk factor in the development of many
chronic medical conditions including cancer [1, 2]. To
enhance the well-being of an increasingly aged
population, and to identify new avenues for therapeutic
intervention, it is crucial that we understand the
molecular basis underlying aging and age-related
diseases. Aging can be defined as the “progressive
deterioration of virtually every bodily function over
time” [3] ultimately resulting in death. At the cellular
level, aging is associated with an increase in DNA
lesions, together, with defects in DNA repair
mechanisms. Of particular relevance is DNA damage
associated with critically shortened telomeres.
Telomeres, which cap the ends of chromosomes, consist
of hexameric TTAGGG repeats and the protective
“shelterin” protein complex [4]. Due to the “end
replication problem”, telomeres shorten during each
replication cycle and critically shortened telomeres
elicit a persistent DNA damage response that triggers an
irreversible growth arrest (senescence). Shortened
Research Perspective
telomeres limit the regenerative capacity of tissues and
are associated with increased age and a variety of
medical conditions including Dykeratosis Congenita,
aplastic anemia, and pulmonary fibrosis [5, 6]. In germ
cells, stem cells and ~85% of cancers, telomere length is
maintained by telomerase, a ribonucleoprotein
consisting of a reverse transcriptase (TERT) and its
RNA moiety (TERC); expression of telomerase renders
cells immortal.
Two segmental premature aging diseases that clinically
appear to present as accelerated aging in some tissues,
are Werner syndrome and Hutchinson-Gilford Progeria
(HGPS). In both diseases recent evidence indicates that
mutations in the genes responsible for these premature
aging diseases result in increased DNA damage,
particularly at telomeres. Although shortening and/or
damage to telomeres is associated with proliferative
arrest of cells in vitro, it remains unclear how accurately
these diseases recapitulate the processes of tissue aging
in humans. Here we discuss recent advances, using in
vitro cell culture and mouse models of progeroid
Accelerated aging syndromes, are they relevant to normal human 
aging? 
Oliver Dreesen and Colin L. Stewart    
 
Institute of Medical Biology, 8A Biomedical Grove, #06‐06 Immunos, 138648 Singapore 
 
Key words: Aging, Hutchinson‐Gilford Progeria, Werner syndrome, DNA damage, telomeres, Wnt signaling, Lef1 
Received: 6/22/11; Accepted: 9/14/11; Published: 9/14/11 
Correspondence to: Colin L. Stewart, PhD;     E‐mail:  colin.stewart@imb.a‐star.edu.sg 
 
Copyright: © Dreesen and Stewart. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited 
Abstract: Hutchinson‐Gilford Progeria (HGPS) and Werner syndromes are diseases that clinically resemble some aspects of
accelerated aging. HGPS is caused by mutations in the LMNA gene resulting in post‐translational processing defects that
trigger Progeria in children. Werner syndrome, arising from mutations in the WRN helicase gene, causes premature aging in
young adults. What are the molecular mechanism(s) underlying these disorders and what aspects of the diseases resemble
physiological  human  aging?  Much  of  what  we  know  stems  from  the  study  of  patient  derived  fibroblasts  with  both
mutations resulting in increased DNA damage, primarily at telomeres. However, in vivo patients with Werner’s develop
arteriosclerosis, among other pathologies. In HGPS patients, including iPS derived cells from HGPS patients, as well as some
mouse  models  for  Progeria,  vascular  smooth  muscle  (VSM)  appears  to  be  among  the  most  severely  affected  tissues.
Defective Lamin processing, associated with DNA damage, is present in VSM from old individuals, indicating processing
defects may be a factor in normal aging. Whether persistent DNA damage, particularly at telomeres, is the root cause for
these pathologies remains to be established, since not all progeroid Lmna mutations result in DNA damage and genome
instability.   
  www.impactaging.com AGING, September 2011, Vol 3 No 9
 
 
www.impactaging.com                   889                                    AGING,  September 2011, Vol.3 No.9
syndromes to highlight important questions that remain:
A) what is the molecular mechanism of how such
seemingly unrelated proteins cause similar degenerative
diseases? B) are these mechanisms representative of
normal aging?
Werner Syndrome and Hutchinson-Gilford Progeria
Werner syndrome is caused by mutations in the Werner
RecQ helicase, a DNA helicase/exonuclease [7]
whereas HGPS is caused by mutations in Lamin A
(LMNA) [8, 9]. The Wrn RecQ helicase is involved in
repair of double strand DNA breaks and in faithful
replication of lagging-strand telomeres. In its mutated
form, WRN causes sporadic loss of telomeres generated
by lagging strand synthesis, increased DNA damage
(presumably caused by critically shortened telomere(s)),
premature senescence and genomic instability [10, 11].
These phenotypes are suppressed in the presence of
telomerase [10, 12, 13]. In Werner syndrome, telomere
dysfunction is causal to the accumulation of DNA
damage foci and results in premature senescence in
vitro. These defects may, therefore, underlie the in vivo
disease etiology.
The A-type lamins are nuclear intermediate filament
proteins that form the nuclear lamina. The lamina
underlies the inner nuclear membrane (INM) and is
important in maintaining interphase nuclear shape,
mechanical integrity and also functions as a scaffold for
other nuclear proteins, some of which regulate DNA
replication and transcription. The most intriguing aspect
of the lamins, particularly LaminA, is that some dozen or
so diseases, the laminopathies, are caused by different
mutations in the Lmna gene. These diseases affect tissues
primarily of mesenchymal origin, resulting in defective
muscle and cardiac function, fat deposition, skeletal
homeostasis and vascular integrity [14].
A critical feature of LaminA is that the protein
undergoes significant post-translational processing. The
processing involves farnesylation of the C-terminal
cysteine, which is thought to promote the association of
the LaminA protein with the INM. The farnesylated
LaminA protein then undergoes two proteolytic
cleavage steps, by the endoprotease ZMPSTE24,
culminating in the removal of the farnesyl group and the
18 C-terminal amino acids. In HGPS, the most common
cause is a point mutation in the LMNA gene, which
creates a novel splice site, removing 50 amino acids
from the C-terminal globular domain. The deletion
includes the ZMPSTE24 endoproteolytic site, resulting
in the synthesis of a truncated, farnesylated form of
LaminA, called Progerin [8, 9]. To what extent the
deletion and/or the persistent farnesylation is the
molecular basis to HGPS is unclear, as a mouse model
of HGPS expressing the truncated, but non-farnesylated
variant of Progerin still develop progeroid symptoms
[15] and non farnesylated Progerin in human cells
elicits the same DNA damage responses as farnesylated
Progerin [16]. In addition, other patients, diagnosed
with Progeria or, intriguingly with atypical Werner’s
syndrome, have mis-sense mutations elsewhere in the
Lmna gene and it seems unlikely that these mutations
affect endoproteolytic cleavage or farnesyl processing,
although this needs to be confirmed [17]. Progerin
results in abnormal nuclear morphologies, altered
chromatin organization, delayed mitosis, lamina
thickening, and growth arrest [18-20]. However
increasing evidence suggests that at least one
underlying cause is that Progerin damages telomeres.
First, and in parallel with their limited proliferative
capacity, progeric fibroblasts have significantly shorter
telomeres than age-matched controls [21, 22]. Secondly,
expressing Progerin in wild-type fibroblasts gradually
inhibits their proliferation. Strikingly, proliferative
inhibition is reversed by telomerase activation and to
some extent by p53-deficiency [23], suggesting that
Progerin directly or indirectly damages telomeres, thus
activating p53, but the damage is reversed by
telomerase. Thirdly, persistent activation of DNA
damage checkpoints and increased numbers of DNA
damage foci are present in HGPS-patient derived
fibroblasts [16, 24, 25]. Increased DNA damage is a
classic feature of cells undergoing senescence due to
shortened or deprotected telomeres [26, 27]. The DNA
damage foci co-localize with human TRF1, a
component of the shelterin complex, and the DNA
damage sensor H2A-X is also expressed and enriched at
telomeric DNA [28]. In addition, live cell imaging and
cytometric analysis indicate that telomeres in Progeria
patient-derived cells are hypermobile [29], a
characteristic of de-protected telomeres [30]. Lastly,
many of these Progerin induced defects, are suppressed
by expression of telomerase in fibroblasts [23, 28].
Together, increased DNA damage, as well as the
shortened telomeres in HGPS, are considered as
characteristics of normal human aging. However a
significant difference is that during normal aging,
telomere dysfunction is mainly a consequence of the
end replication problem, which may also be enhanced
by DNA damaging agents such as oxidative stress [31].
In HGPS, telomeres may be directly damaged by
Progerin. However, the precise mechanism by which
telomeres are damaged, and whether only a subset of
telomeres, such as those located at the nuclear
periphery, still needs to be established. How well do
these in vitro cell culture results recapitulate the in vivo
pathologies in patients and mouse models of Progeria?
 
 
www.impactaging.com                   890                                    AGING,  September 2011, Vol.3 No.9
Mouse models of HGPS and Werner syndrome
The role of DNA damage resulting in accelerated aging
has been recapitulated in a number of mouse models
(reviewed by Schumacher et al. [32]). One example is
the XPF-ERCC1-deficient mouse. XPF-ERCC1 is
required for nucleotide excision repair, and repairs
DNA lesions due to UV radiation. XPF-ERCC1-
deficient mice exhibit slightly retarded embryonic and
post-natal development, followed by growth arrest by
~2 weeks, and death at ~4 weeks after birth.
Phenotypically, these mice show aged-like phenotypes
in skin, liver and bone marrow. XPF-ERCC1 cells
prematurely senesce and are more sensitive to oxidative
stress [33]. Two mouse models for Werner syndrome
were generated by deletion of the Wrn gene, but neither
recapitulated any accelerated aging phenotypes
observed in humans or in cultured cells [34, 35]. This
discrepancy was thought to be due to laboratory mice
having extremely long telomeres and residual levels of
telomerase in some somatic tissues [36, 37].
Accordingly, the additional deletion of terc (the RNA
component of telomerase) in Wrn mice resulted in
shortened telomeres, with the appearance of the classic
phenotypes of accelerated aging, i.e. grey hair,
osteoporosis, alopecia and premature death [38].
Embryonic fibroblasts (MEFs) from these mice
exhibited genomic instability, increased levels of DNA
damage and senesced prematurely, corroborating
previous results [38]. Interestingly, in contrast to
telomerase-deficient mice, in which the degenerative
phenotypes manifest mainly in highly proliferative
tissues (intestine, skin and blood), in Wrn-/-
/Terc-/-
mice,
tissues of mesenchymal origin were mainly affected
resulting in osteoporosis, cataracts and diabetes [38].
Several HGPS-progeroid mouse models have been
established to investigate how Lmna mutations,
including defective processing of normal Lamin A, may
accelerate aging [39-45]. The first Lmna mutant
showing premature aging was generated by a splicing
defect deleting exon 9, resulting in an in frame deletion
of 40 amino acids in the C-terminal domain
(LmnaL530P/L530P
; also called ∆9Lmna) [39]. The
mutation, like Progerin, results in a truncated variant of
LaminA that remains farnesylated, although the ∆9
protein is expressed at about 10% that of wild-type
levels. At birth, homozygotes were indistinguishable
from their wild-type littermates. However, post-nataly,
they exhibit a rapid onset of severe growth retardation,
loss of subcutaneous fat, poor heart development,
skeletal abnormalities, decreased hair follicle density,
culminating in death at 3-4 weeks. Postnatal ∆9Lmna
fibroblasts (MAFs), established from several different
tissues, show a highly restricted proliferative capability
with early death. Although ∆9Lmna MAFs do exhibit
abnormal nuclear morphologies, premature death of the
cells was not associated with overt chromosomal
defects such as aneuploidy or increased DNA damage.
Loss of the MAFs proliferative capability was due to
reduced synthesis of some 30 extracellular matrix
proteins (ECM), since serial culture of the ∆9Lmna
fibroblasts on ECM deposited by normal MAFs
sustained their proliferation. Surprisingly, and in
contrast to the MAFs, the growth properties of ∆9Lmna
embryonic fibroblasts (MEFs) were practically
indistinguishable from their wild type counterparts,
despite having defective nuclear morphologies, and
identical ∆9Lmna expression levels to MAFs [45].
These findings revealed an unexpected difference
between embryonic and post-natal fibroblasts in their
susceptibility to ∆9Lmna, suggesting a possible
explanation as to why progeric children are overtly
normal at birth, since A-type lamins (and probably
Progerin) are expressed during development [46-48].
One significant molecular difference between MEFs
and MAFs is that MAFs express higher levels of the
Wnt regulated transcription factor Lef1, compared to
MEFs. Similar differences in LEF1 levels were also
noted in normal human fibroblasts with 12-16 week old
fetal fibroblasts expressing reduced levels of LEF1
compared to those from a 17-year old individual
(unpublished observations). In the ∆9Lmna MAFs Lef1
levels were markedly reduced, due to ∆9Lmna
inhibition of canonical Wnt signaling. LEF1 levels
were also significantly reduced in fibroblasts
established from two HGPS children, indicating that
different truncated, farnesylated LMNA mutant proteins
inhibit LEF1 expression and function. Some of the
ECM genes, whose expression was reduced by
∆9Lmna, are transcriptionally regulated by Lef1
indicating a direct link between the inhibition of ECM
gene expression and ∆9Lmna. The finding that ECM
expression was significantly reduced in the ∆9Lmna
model was similar to microarray studies on HGPS
fibroblasts and MSCs, where ECM gene expression was
also profoundly altered [48-50].
Loss of the endoprotease ZMPSTE24 results in the
persistence of unprocessed, farnesylated, full length pre-
laminA. Mice lacking ZMPSTE24 develop progeroid
features which include skeletal abnormalities, alopecia
and death by 6 months, [24, 41, 43]. In contrast to
mice, the few humans identified with ZMPSTE24
deficiency, develop restrictive dermopathy (RD) or tight
skin, resulting in perinatal mortality [51]. Cells,
including MEFs, from Zmpste24 null mice show
increased cellular DNA damage, together with defective
DNA damage responses, as well as defective Wnt
 
 
www.impactaging.com                   891                                   AGING,  September 2011, Vol.3 No.9
signaling in the hair follicles [52]. The accelerated
aging phenotype of Zmpste24-/-
mouse was partly
alleviated when crossed into a p53-deficient background
[40] and completely rescued when made heterozygous
for Lmna expression revealing a dosage effect of pre-
laminA on the pathology [40]. Analysis of fibroblasts
from one patient with RD also revealed persistent
activation of DNA damage checkpoints [16]. Why
ZMPSTE24 loss in humans results in a more severe
(peri-natal) pathology than in mice is unclear, although
it is possible that mice may be more “resistant” to
Zmpste24 deficiency because of their longer telomeres.
These results reflect the in vitro results reported by
Kudlow et al., and others [23, 28] in which inhibition of
p53 signaling rescued the Progerin-induced DNA
damage and impaired proliferation. However, it is still
unclear whether Zmpste24-deficiency damages
telomeres in a similar way to Progerin.
In other progeroid mouse lines, Lmna was replaced with
a variant allele that only expresses Progerin (LmnaHG/+
).
At birth these mice were overtly normal with the
LmnaHG/+
heterozygotes showing retarded postnatal
growth, weight loss, diminished adipose tissue, skeletal
defects and death by nine months [53]. The few
homozygotes produced, showed severe growth
retardation and all died by three weeks. In contrast to
Zmpste24–/–
mice, skeletal muscle function was
unaffected and, as with the ∆9Lmna mice, no pathology
was detected in the ascending aorta, although the state
of the great vessels was not reported. It is noteworthy
that all three mouse lines show similar pathologies in
mesenchymal tissues, with the skeletal system, being
predominantly affected.
In addition to these three lines where the indigenous
Lmna gene was modified, transgenic lines were derived
in which Progerin was expressed as a transgene. In two
of the transgenic lines Progerin was specifically
expressed in the skin and resulted in abnormal nuclear
morphologies and in one line, epidermal hyperplasia,
hyperparakeratosis, hyperplasia of the sebaceous
glands, culminating subcutaneous fat loss, dermal
fibrosis and hypoplastic sebaceous glands and dental
defects [54, 55]. In the third line, no overt effect was
noted, however, by one year, loss of vascular smooth
muscle was detected in the aorta [42].
How do these findings explain that HGPS patients die
in their early to mid teens from atherosclerosis and does
this relate to normal aging? Post-mortem analyses of a
few HGPS patients revealed extensive loss of vascular
smooth muscle (VSM), particularly in the aorta and
great vessels proximal to the heart and, in two others,
extensive atherosclerosis [56, 57]. In two progeroid
mouse models, extensive loss of VSM in both the aorta
and great vessels proximal to the heart was present. In
the ∆9Lmna mutant mice, a rapid onset of VSM loss,
together with increased apoptosis in the great vessels
proximal to the heart was apparent at 2 weeks of age.
These mice also exhibited extensive reduction in many
ECM genes expressed in the skeletal system together
with reduced trabecularity and minerality in the
calvarial and axial skeleton, features consistent with the
skeletal pathology found in HGPS. In the transgenic
model [42], the human Progerin transgene resulted in
loss of VSM in the aorta, but only after one year.
Similarly, Werner’s patients show accelerated
atherosclerosis and death from myocardial infarction,
despite normal circulating cholesterol levels. This
suggests that cardiovascular defects are frequently
associated with increased DNA damage and/or that the
cardiovascular system is particularly sensitive or
susceptible to DNA damage [58].
The ∆9Lmna mutant phenocopies many of the tissue,
cellular and molecular pathologies characteristic of
Progeria, yet, a number of interesting discrepancies
exist. How does the ∆9Lmna mutation lead to
decreased Wnt-signaling, and does this, in turn,
exclusively reduce ECM synthesis? Progerin inhibits
Wnt signaling to a lesser extent than the ∆9Lmna
mutant, although progeric fibroblasts show reduced
levels of Lef1 and treatment with a GSK-3 inhibitor
improves their proliferation [45]. Moreover, what is the
role of DNA damage in the ∆9Lmna mice since there
was no evidence of increased genomic instability or an
increase in H2A-X foci? If so, how, and to what extent
could wild type ECM restore this phenotype? Are the
farnesylated, truncated variants of LaminA, defective in
Wnt signaling, telomere damage and disrupted ECM
expression somehow interlinked? Some (or all?) of
these parameters are clearly affected during normal
ageing, but why are they especially critical to the
vascular system? One common link maybe through the
Forkhead box O (FoxO) transcription factor network.
Oxidative stress activates these factors, which in turn
inhibit Wnt mediated transcription by competing for β-
catenin. Inhibition of FOXO mediated transcription
factor activity improves VSM viability and promotes
osteoblast differentiation [59].
Differences in telomere length and maintenance between
mice and humans are an important consideration when
generating mouse models for Werner syndrome and
Ataxia telangectasia; in both cases Wrn-/- and Atm-/-
deficient mice exhibited progeriod features only after
they were crossed into a telomerase-deficient background
[38, 60]. However the role of DNA damage in the
molecular pathology of HGPS remains open. Mouse
 
 
www.impactaging.com                   892                                   AGING,  September 2011, Vol.3 No.9
models that seemingly do not show DNA damage still
develop a progeroid phenotype. Furthermore, other
progeroid/atypical Werner’s cases, caused by LMNA
mutations, have not been investigated as to whether these
mutations result in DNA damage.
HGPS is complex, although some understanding of the
molecular pathology has been gained by the study of
patient-derived fibroblasts, ectopically expressed
proteins in normal human fibroblasts and mouse
models. Nevertheless, we still lack a clear picture how
(and if) Progerin, Wnt signaling, the ECM, DNA
damage and telomeres are interconnected. Two recently
generated in vitro disease models for Progeria using
induced pluripotent stem cells (iPSC) provide further
insights [48, 61]. iPSC do not express Lamin A (or
Progerin), are overtly normal, and can differentiate into
relevant tissues that are particularly affected in Progeria
patients (i.e. mesenchymal lineages, vascular smooth
muscle etc), and which cannot be derived from patients.
From such “disease in a dish” studies it was apparent
that VSM and mesenchymal stem cells were especially
sensitive to Progerin, possibly because they expressed
the highest levels of Progerin-LaminA, relative to other
cell types, such as endothelial and neuronal lineages. It
was noted that the HGPS-MSCs showed elevated levels
of DNA damage and were far less efficient than normal
MSCs at rescuing vascular circulation following
ischemia [46]. In addition, comparison of gene
expression profiles between MSCs derived from normal
individuals and HGPS-MSCs, it was striking that Gene
Ontology analysis revealed both Extracellular Matrix
and Wnt signaling to be the most significant differences
between the HGPS- and normal MSCs [48].
However the recurring question is do progeric diseases
tell us something about the normal ageing process? In a
recent study, VSM isolated from arteries from a limited
number of 70-80 year old individuals, expressed
elevated levels of pre-laminA, the farnesylated
precursor of mature LaminA, whereas in the arteries
from teenagers no pre-lamin A was detected [62]. This
increase of pre-laminA was due to decreased levels of
ZMPSTE24 in the VSM, possibly as a consequence of
ZMPSTE24 expression being sensitive to oxidative
stress. VSM cells appear to be particularly vulnerable to
the anti-proliferative effects of pre-laminA, as
suggested by VSM derived from HGPS iPS cells [48].
Why VSM should be seemingly sensitive to Progerin is
unclear, but it maybe relevant that in skin biopsies from
HGPS patients, VSM expressed the highest levels of
Progerin [18, 48]. Several studies have also suggested
that low levels of Progerin protein may be detected in
tissues from aged individuals [62, 63]. It is conceivable
that part of the normal aging process, is a decline in
vascular integrity due to defective LaminA processing.
Defective processing may arise either due to a decrease
in ZMPSTE24 activity and/or defective splicing
resulting in low but significant levels of Progerin being
produced [63]. In addition, it remains to be established
to what extent the other tissue pathologies in HGPS,
arise either through autonomous cell expression of
Progerin or are a consequence of the vascular defects.
These issues and whether defective LaminA processing
enhances telomeric DNA damage, inhibits Wnt
signaling and ECM regulation, all of which may
contribute to the normal process of aging, are all
testable propositions.
ACKNOWLEDGMENTS
We thank the Singapore Biomedical Research Council
and the Singapore Agency for Science, Technology and
Research (A*STAR) for supporting us in this work.
CONFLICT OF INTERESTS STATEMENT
The authors of this manuscript have no conflict of
interest to declare.
REFERENCES
1.  Wright  WE,  Shay  JW.  Historical  claims  and  current 
interpretations  of  replicative  aging.  Nat  Biotechnol.  2002;  20: 
682‐688. 
2. Sahin E, Depinho RA. Linking functional decline of telomeres, 
mitochondria and stem cells during ageing. Nature. 2010; 464: 
520‐528. 
3. Austad SN. Comparative aging and life histories in mammals. 
Exp Gerontol. 1997; 32: 23‐38. 
4. de Lange T. How telomeres solve the end‐protection problem. 
Science. 2009; 326: 948‐952. 
5.  Armanios  M.  Syndromes  of  telomere  shortening.  Annu  Rev 
Genomics Hum Genet. 2009; 10: 45‐61. 
6. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009; 
361: 2353‐2365. 
7.  Yu  CE,  Oshima  J,  Fu  YH,  Wijsman  EM,  Hisama  F,  Alisch  R, 
Matthews S, Nakura J, Miki T, Ouais S, Martin GM, Mulligan J, 
and  Schellenberg  GD.  Positional  cloning  of  the  Werner's 
syndrome gene. Science. 1996; 272: 258‐262. 
8. De Sandre‐Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, 
Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, and 
Levy  N.  Lamin  a  truncation  in  Hutchinson‐Gilford  progeria. 
Science. 2003; 300: 2055. 
9. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott 
L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, 
Durkin  S,  Csoka  AB,  Boehnke  M,  Glover  TW,  and  Collins  FS. 
Recurrent de novo point mutations in lamin A cause Hutchinson‐
Gilford progeria syndrome. Nature. 2003; 423: 293‐298. 
10. Crabbe L, Verdun RE, Haggblom CI, and Karlseder J. Defective 
telomere lagging strand synthesis in cells lacking WRN helicase 
activity. Science. 2004; 306: 1951‐1953. 
 
 
www.impactaging.com                   893                                   AGING, September 2011, Vol.3 No.9
11.  Opresko  PL,  Cheng  WH,  and  Bohr  VA.  Junction  of  RecQ 
helicase  biochemistry  and  human  disease.  J  Biol  Chem.  2004; 
279: 18099‐18102. 
12.  Crabbe  L,  Jauch  A,  Naeger  CM,  Holtgreve‐Grez  H,  and 
Karlseder  J.  Telomere  dysfunction  as  a  cause  of  genomic 
instability in Werner syndrome. Proc Natl Acad Sci U S A. 2007; 
104: 2205‐2210. 
13.  Wyllie  FS,  Jones  CJ,  Skinner  JW,  Haughton  MF,  Wallis  C, 
Wynford‐Thomas  D,  Faragher  RG,  and  Kipling  D.  Telomerase 
prevents  the  accelerated  cell  ageing  of  Werner  syndrome 
fibroblasts. Nat Genet. 2000; 24: 16‐17. 
14.  Burke  B,  Stewart  CL.  The  laminopathies:  the  functional 
architecture of the nucleus and its contribution to disease. Annu 
Rev Genomics Hum Genet. 2006; 7: 369‐405. 
15. Yang SH, Andres DA, Spielmann HP, Young SG, and Fong LG. 
Progerin elicits disease phenotypes of progeria in mice whether 
or not it is farnesylated. J Clin Invest. 2008; 118: 3291‐3300. 
16.  Liu  Y,  Rusinol  A,  Sinensky  M,  Wang  Y,  and  Zou  Y.  DNA 
damage responses in progeroid syndromes arise from defective 
maturation of prelamin A. J Cell Sci. 2006; 119: 4644‐4649. 
17. Csoka AB, Cao H, Sammak PJ, Constantinescu D, Schatten GP, 
and  Hegele  RA.  Novel  lamin  A/C  gene  (LMNA)  mutations  in 
atypical progeroid syndromes. J Med Genet. 2004; 41: 304‐308. 
18. McClintock D, Gordon LB, and Djabali K. Hutchinson‐Gilford 
progeria mutant lamin A primarily targets human vascular cells 
as detected by an anti‐Lamin A G608G antibody. Proc Natl Acad 
Sci U S A. 2006; 103: 2154‐2159. 
19. Scaffidi P, Misteli T. Reversal of the cellular phenotype in the 
premature aging disease Hutchinson‐Gilford progeria syndrome. 
Nat Med. 2005; 11: 440‐445. 
20.  Dechat  T,  Shimi  T,  Adam  SA,  Rusinol  AE,  Andres  DA, 
Spielmann  HP,  Sinensky  MS,  and  Goldman  RD.  Alterations  in 
mitosis and cell cycle progression caused by a mutant lamin A 
known  to  accelerate  human  aging.  Proc  Natl  Acad  Sci  U  S  A. 
2007; 104: 4955‐4960. 
21. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, 
Futcher  AB,  Greider  CW,  and  Harley  CB.  Telomere  length 
predicts  replicative  capacity  of  human  fibroblasts.  Proc  Natl 
Acad Sci U S A. 1992; 89: 10114‐10118. 
22. Decker ML, Chavez E, Vulto I, and Lansdorp PM. Telomere 
length  in  Hutchinson‐Gilford  progeria  syndrome.  Mech  Ageing 
Dev. 2009; 130: 377‐383. 
23.  Kudlow  BA,  Stanfel  MN,  Burtner  CR,  Johnston  ED,  and 
Kennedy BK. Suppression of proliferative defects associated with 
processing‐defective lamin A mutants by hTERT or inactivation 
of p53. Mol Biol Cell. 2008; 19: 5238‐5248. 
24. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang 
JD,  Li  KM,  Chau  PY,  Chen  DJ,  Pei  D,  Pendas  AM,  Cadinanos  J, 
Lopez‐Otin  C,  Tse  HF,  Hutchison  C,  Chen  J,  Cao  Y,  Cheah  KS, 
Tryggvason K, and Zhou Z. Genomic instability in laminopathy‐
based premature aging. Nat Med. 2005; 11: 780‐785. 
25.  Musich  PR,  Zou  Y.  Genomic  instability  and  DNA  damage 
responses  in  progeria  arising  from  defective  maturation  of 
prelamin A. Aging (Albany NY). 2009; 1: 28‐37. 
26. d'Adda di Fagagna F, Reaper PM, Clay‐Farrace L, Fiegler H, 
Carr P, Von Zglinicki T, Saretzki G, Carter NP, and Jackson SP. A 
DNA  damage  checkpoint  response  in  telomere‐initiated 
senescence. Nature. 2003; 426: 194‐198. 
27. Takai H, Smogorzewska A, and de Lange T. DNA damage foci 
at dysfunctional telomeres. Curr Biol. 2003; 13: 1549‐1556. 
28.  Benson  EK,  Lee  SW,  and  Aaronson  SA.  Role  of  progerin‐
induced  telomere  dysfunction  in  HGPS  premature  cellular 
senescence. J Cell Sci. 2010; 123: 2605‐2612. 
29. De Vos WH, Houben F, Hoebe RA, Hennekam R, van Engelen 
B, Manders EM, Ramaekers FC, Broers JL, and Van Oostveldt P. 
Increased plasticity of the nuclear envelope and hypermobility of 
telomeres  due  to  the  loss  of  A‐type  lamins.  Biochim  Biophys 
Acta. 2010; 1800: 448‐458. 
30.  Dimitrova  N,  Chen  YC,  Spector  DL,  and  de  Lange  T.  53BP1 
promotes  non‐homologous  end  joining  of  telomeres  by 
increasing chromatin mobility. Nature. 2008; 456: 524‐528. 
31. Wang C, Jurk D, Maddick M, Nelson G, Martin‐Ruiz C, and 
von Zglinicki T. DNA damage response and cellular senescence in 
tissues of aging mice. Aging Cell. 2009; 8: 311‐323. 
32.  Schumacher  B,  Garinis  GA,  and  Hoeijmakers  JH.  Age  to 
survive: DNA damage and aging. Trends Genet. 2008; 24: 77‐
85. 
33. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, 
Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen 
W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer 
WJ,  Vijg  J,  Jaspers  NG,  and  Hoeijmakers  JH.  A  new  progeroid 
syndrome  reveals  that  genotoxic  stress  suppresses  the 
somatotroph axis. Nature. 2006; 444: 1038‐1043. 
34.  Lebel  M,  Leder  P.  A  deletion  within  the  murine  Werner 
syndrome  helicase  induces  sensitivity  to  inhibitors  of 
topoisomerase  and  loss  of  cellular  proliferative  capacity.  Proc 
Natl Acad Sci U S A. 1998; 95: 13097‐13102. 
35. Lombard DB, Beard C, Johnson B, Marciniak RA, Dausman J, 
Bronson R, Buhlmann JE, Lipman R, Curry R, Sharpe A, Jaenisch 
R,  and  Guarente  L.  Mutations  in  the  WRN  gene  in  mice 
accelerate  mortality  in  a  p53‐null  background.  Mol  Cell  Biol. 
2000; 20: 3286‐3291. 
36. Hemann MT, Greider CW. Wild‐derived inbred mouse strains 
have short telomeres. Nucleic Acids Res. 2000; 28: 4474‐4478. 
37. Prowse KR,  Greider CW. Developmental and tissue‐specific 
regulation of mouse telomerase and telomere length. Proc Natl 
Acad Sci U S A. 1995; 92: 4818‐4822. 
38.  Chang  S,  Multani  AS,  Cabrera  NG,  Naylor  ML,  Laud  P, 
Lombard D, Pathak S, Guarente L, and DePinho RA. Essential role 
of limiting telomeres in the pathogenesis of Werner syndrome. 
Nat Genet. 2004; 36: 877‐882. 
39. Mounkes LC, Kozlov S, Hernandez L, Sullivan T, and Stewart 
CL. A progeroid syndrome in mice is caused by defects in A‐type 
lamins. Nature. 2003; 423: 298‐301. 
40.  Varela  I,  Cadinanos  J,  Pendas  AM,  Gutierrez‐Fernandez  A, 
Folgueras  AR,  Sanchez  LM,  Zhou  Z,  Rodriguez  FJ,  Stewart  CL, 
Vega JA, Tryggvason K, Freije JM, and Lopez‐Otin C. Accelerated 
ageing in mice deficient in Zmpste24 protease is linked to p53 
signalling activation. Nature. 2005; 437: 564‐568. 
41. Pendas AM, Zhou Z, Cadinanos J, Freije JM, Wang J, Hultenby 
K,  Astudillo  A,  Wernerson  A,  Rodriguez  F,  Tryggvason  K,  and 
Lopez‐Otin C. Defective prelamin A processing and muscular and 
adipocyte  alterations  in  Zmpste24  metalloproteinase‐deficient 
mice. Nat Genet. 2002; 31: 94‐99. 
42. Varga R, Eriksson M, Erdos MR, Olive M, Harten I, Kolodgie F, 
Capell BC, Cheng J, Faddah D, Perkins S, Avallone H, San H, Qu X, 
Ganesh S, Gordon LB, Virmani R, Wight TN, Nabel EG, and Collins 
FS. Progressive vascular smooth muscle cell defects in a mouse 
model of Hutchinson‐Gilford progeria syndrome. Proc Natl Acad 
Sci U S A. 2006; 103: 3250‐3255. 
 
 
www.impactaging.com                   894                                   AGING, September 2011, Vol.3 No.9
43. Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, 
Mohr A, Meta M, Genant H, Jiang Y, Wisner ER, Van Bruggen N, 
Carano  RA,  Michaelis  S,  Griffey  SM,  and  Young  SG.  Zmpste24 
deficiency  in  mice  causes  spontaneous  bone  fractures,  muscle 
weakness, and a prelamin A processing defect. Proc Natl Acad 
Sci U S A. 2002; 99: 13049‐13054. 
44.  Yang  SH,  Meta  M,  Qiao  X,  Frost  D,  Bauch  J,  Coffinier  C, 
Majumdar  S,  Bergo  MO,  Young  SG,  and  Fong  LG.  A 
farnesyltransferase  inhibitor  improves  disease  phenotypes  in 
mice with a Hutchinson‐Gilford progeria syndrome mutation. J 
Clin Invest. 2006; 116: 2115‐2121. 
45.  Hernandez  L,  Roux  KJ,  Wong  ES,  Mounkes  LC,  Mutalif  R, 
Navasankari R, Rai B, Cool S, Jeong JW, Wang H, Lee HS, Kozlov 
S, Grunert M, Keeble T, Jones CM, Meta MD, Young SG, Daar IO, 
Burke  B,  Perantoni  AO,  and  Stewart  CL.  Functional  coupling 
between  the  extracellular  matrix  and  nuclear  lamina  by  Wnt 
signaling in progeria. Dev Cell. 2010; 19: 413‐425. 
46.  Stewart  C,  Burke  B.  Teratocarcinoma  stem  cells  and  early 
mouse embryos contain only a  single major lamin polypeptide 
closely resembling lamin B. Cell. 1987; 51: 383‐392. 
47.  Rober  RA,  Weber  K,  and  Osborn  M.  Differential  timing  of 
nuclear lamin A/C expression in the various organs of the mouse 
embryo  and  the  young  animal:  a  developmental  study. 
Development. 1989; 105: 365‐378. 
48.  Zhang  J,  Lian  Q,  Zhu  G,  Zhou  F,  Sui  L,  Tan  C,  Mutalif  RA, 
Navasankari  R,  Zhang  Y,  Tse  HF,  Stewart  CL,  and  Colman  A.  A 
Human  iPSC  Model  of  Hutchinson  Gilford  Progeria  Reveals 
Vascular  Smooth  Muscle  and  Mesenchymal  Stem  Cell  Defects. 
Cell Stem Cell. 2011; 8: 31‐45. 
49. Csoka AB, English SB, Simkevich CP, Ginzinger DG, Butte AJ, 
Schatten  GP,  Rothman  FG,  and  Sedivy  JM.  Genome‐scale 
expression  profiling  of  Hutchinson‐Gilford  progeria  syndrome 
reveals  widespread  transcriptional  misregulation  leading  to 
mesodermal/mesenchymal  defects  and  accelerated 
atherosclerosis. Aging Cell. 2004; 3: 235‐243. 
50.  Scaffidi  P,  Misteli  T.  Lamin  A‐dependent  misregulation  of 
adult stem cells associated with accelerated ageing. Nat Cell Biol. 
2008; 10: 452‐459. 
51. Navarro CL, Cadinanos J, De Sandre‐Giovannoli A, Bernard R, 
Courrier S, Boccaccio I, Boyer A, Kleijer WJ, Wagner A, Giuliano F, 
Beemer  FA,  Freije  JM,  Cau  P,  Hennekam  RC,  Lopez‐Otin  C, 
Badens  C,  and  Levy  N.  Loss  of  ZMPSTE24  (FACE‐1)  causes 
autosomal recessive restrictive dermopathy and accumulation of 
Lamin A precursors. Hum Mol Genet. 2005; 14: 1503‐1513. 
52. Espada J, Varela I, Flores I, Ugalde AP, Cadinanos J, Pendas 
AM, Stewart CL, Tryggvason K, Blasco MA, Freije JM, and Lopez‐
Otin C. Nuclear envelope defects cause stem cell dysfunction in 
premature‐aging mice. J Cell Biol. 2008; 181: 27‐35. 
53. Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta 
M, Bendale P, Gelb MH, Young SG, and Fong LG. Blocking protein 
farnesyltransferase  improves  nuclear  blebbing  in  mouse 
fibroblasts  with  a  targeted  Hutchinson‐Gilford  progeria 
syndrome mutation. Proc Natl Acad Sci U S A. 2005; 102: 10291‐
10296. 
54.  Sagelius  H,  Rosengardten  Y,  Hanif  M,  Erdos  MR,  Rozell  B, 
Collins FS, and Eriksson M. Targeted transgenic expression of the 
mutation causing Hutchinson‐Gilford progeria syndrome leads to 
proliferative  and  degenerative  epidermal  disease.  J  Cell  Sci. 
2008; 121: 969‐978. 
55. Wang Y, Panteleyev AA, Owens DM, Djabali K, Stewart CL, 
and  Worman  HJ.  Epidermal  expression  of  the  truncated 
prelamin  A  causing  Hutchinson‐Gilford  progeria  syndrome: 
effects on keratinocytes, hair and skin. Hum Mol Genet. 2008; 
17: 2357‐2369. 
56. Stehbens WE, Wakefield SJ, Gilbert‐Barness E, Olson RE, and 
Ackerman  J.  Histological  and  ultrastructural  features  of 
atherosclerosis in progeria. Cardiovasc Pathol. 1999; 8: 29‐39. 
57. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos 
MR, Blair C, Funke B, Smoot L, Gerhard‐Herman M, Machan JT, 
Kutys R, Virmani R, Collins FS, Wight TN, Nabel EG, and Gordon 
LB.  Cardiovascular  pathology  in  Hutchinson‐Gilford  progeria: 
correlation  with  the  vascular  pathology  of  aging.  Arterioscler 
Thromb Vasc Biol. 2010; 30: 2301‐2309. 
58.  Cohen  JI,  Arnett  EN,  Kolodny  AL,  and  Roberts  WC. 
Cardiovascular features of the Werner syndrome. Am J Cardiol. 
1987; 59: 493‐495. 
59.  Manolagas  SC,  Almeida  M.  Gone  with  the  Wnts:  beta‐
catenin,  T‐cell  factor,  forkhead  box  O,  and  oxidative  stress  in 
age‐dependent diseases of bone, lipid, and glucose metabolism. 
Mol Endocrinol. 2007; 21: 2605‐2614. 
60. Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu 
Y,  Alt  FW,  and  DePinho  RA.  Telomere  dysfunction  and  Atm 
deficiency  compromises  organ  homeostasis  and  accelerates 
ageing. Nature. 2003; 421: 643‐648. 
61. Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang SL, Panopoulos 
AD, Suzuki K, Kurian L, Walsh C, Thompson J, Boue S, Fung HL, 
Sancho‐Martinez  I,  Zhang  K,  Iii  JY,  and  Belmonte  JC. 
Recapitulation of premature ageing with iPSCs from Hutchinson‐
Gilford progeria syndrome. Nature. 2011;  
62. Ragnauth CD, Warren DT, Liu Y, McNair R, Tajsic T, Figg N, 
Shroff  R,  Skepper  J,  and  Shanahan  CM.  Prelamin  A  acts  to 
accelerate  smooth  muscle  cell  senescence  and  is  a  novel 
biomarker  of  human  vascular  aging.  Circulation.  2010;  121: 
2200‐2210. 
63.  Rodriguez  S,  Coppede  F,  Sagelius  H,  and  Eriksson  M. 
Increased  expression  of  the  Hutchinson‐Gilford  progeria 
syndrome  truncated  lamin  A  transcript  during  cell  aging.  Eur  J 
Hum Genet. 2009; 17: 928‐937. 
 
 
 
 
 
www.impactaging.com                   895                                    AGING,  September 2011, Vol.3 No.9
